期刊文献+

环氧化酶-2基因多态性与冠心病易感性的相关性研究 被引量:1

Association of cyclooxygenase-2 gene polymorphism with susceptibility to coronary heart disease
原文传递
导出
摘要 目的探讨环氧化酶-2(COX-2)基因-765G/C多态性与冠心病易感性的关系。方法对226例经冠状动脉造影确诊的冠心病患者和240例正常人进行对照研究。应用聚合酶链反应限制性片断长度多态性技术测定COX-2基因-765G/C多态性。结果COX-2基因-765G/C多态性在冠心病组和正常人群(对照组)中分布的差异有显著性,冠心病组765G等位基因频率明显高于对照组(85.0%比79.4%,P〈0.05)。等位基因频率的相对风险分析发现,G等位基因携带者患冠心病的风险是C等位基因的1.471倍(95%CI:1.044-2.072)。结论COX-2基因启动子-765G/C多态性与冠心病发病具有相关性,其中G等位基因可能是冠心病发病的遗传易感基因。 Objective To investigate the association between cyclooxygenase-2 (COX-2) gene- 765G/C polymorphism and coronary heart disease (CHD) in Chinese population. Methods This was a case-control study,which enrolled 226 CHD patients diagnosed by angiography and 240 healthy controls. The genotype and allele frequencies of COX-2 gene polymorphism were assayed by polymerase chain reac- tion-restricted fragments length polymorphism (PCR-RFLP). Results The distribution of COX-2 gene- 765G/C polymorphism was significantly different between CHD group and control group. The frequency of the COX-2 gene -765G allele in CHD patients was significantly higher than that of the control group( 85. 0% vs 79.4% ,P 〈 0.05). The relative risk for CHD in G allele carriers was 1. 471 times as high as that in C allele carriers ( OR = 1. 471,95% CI : 1. 044 - 2. 072 ). Conclusion COX-2 gene promoter region- 765G/C polymorphism is associated with CHD and G allele may be a risk factor for CHD.
作者 熊涛 林国生
出处 《临床内科杂志》 CAS 2008年第11期786-788,共3页 Journal of Clinical Internal Medicine
关键词 环氧化酶-2 冠心病 限制性片断长度多态性 Cyclooxygenase-2 Coronary heart disease Restricted fragments length polymor- phism
  • 相关文献

参考文献1

二级参考文献6

共引文献15

同被引文献8

  • 1黄震华.非甾体类抗炎药物与心血管疾病危险性[J].中国新药与临床杂志,2007,26(4):315-318. 被引量:7
  • 2Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-in- flammatory drugs in chronic heart failure. Arch Intern Med,2009,169: 141-149.
  • 3Mangoni AA, Woodman R J, Gaganis P, et al. Use of non-steroidal anti- inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmaco1,2010 ,69 :689-700.
  • 4Roumie CL, Choma NN, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, a- cute myocardial infarction, and death from coronary heart disease. Phar- macoepidemiol Drug Saf,2009,18 : 1053-1063.
  • 5Friedewald VE Jr, Bennett JS, Packer M, et al. The Editor's Roundt- able : Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. Am J Cardio1,2008,102 : 1046-1055.
  • 6Farkouh ME, Greenberg BP. An evidence-based review of the cardiovas- cular risks of nonsteroidal anti-inflammatory drugs. Am J Cardio1,2009, 103 : 1227 -1237.
  • 7Chen YF JP, Barton P, Bryan S, et al. Cyclooxygenase-2 selective non- steroidal anti-inflammatory drugs ( etodolac, meloxicam, celecoxib, rofe- coxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess,2008,12 : 1-278.
  • 8唐茜,徐建华,肖会,周小妹.类风湿关节炎合并心血管病变患者血清同型半胱氨酸水平及其与亚甲基四氢叶酸还原酶基因多态性的关系[J].临床内科杂志,2010,27(12):815-817. 被引量:3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部